search icon

    Market Snapshot

    • S&P Futures

      4,285.75

    • Dow Futures

      33,941

    • Nasdaq Futures

      13,555.25

    blog search icon

    Mustang Bio, Inc.

    (NASDAQ:MBIO)

    $0.70

    -$0.04

    -4.86%

    Mustang Bio, Inc. Chart

    MBIO Stock Price Today

    Mustang Bio, Inc. (MBIO) stock declined over -4.86% intraday to trade at $0.7023 a share on NASDAQ. The stock opened with a loss of -6.36% at $0.75 and touched an intraday high of $0.75, falling -1.78% against the last close of $0.715. The stock went to a low of $0.67 during the session.

    Stock Snapshot

    $0.715

    Prev. Close

    74.91 Million

    Market Cap

    $0.67

    Day Low

    $0.75

    Open

    102.95 Million

    Number of Shares

    $0.75

    Day High

    -

    P/E ratio

    -0.77

    EPS (TTM)

    1.19

    Cash Flow per Share

    1.28

    Free Float in %

    1.33

    Book Value

    403,777

    Volume

    Mustang Bio, Inc. Historical Data

    DateOpenHighLowCloseVolume
    2022-08-17$0.75$0.75$0.67$0.7381,734,427
    2022-08-16$0.75$0.75$0.705$0.715468,400
    2022-08-15$0.77$0.773$0.72$0.75590,300
    2022-08-12$0.73$0.776$0.68$0.75665,000
    2022-08-11$0.75$0.795$0.72$0.738594,500
    2022-08-10$0.71$0.738$0.69$0.731674,500
    2022-08-09$0.72$0.75$0.65$0.701485,900
    2022-08-08$0.76$0.78$0.705$0.728505,000
    2022-08-05$0.74$0.78$0.703$0.762780,200
    2022-08-04$0.68$0.75$0.676$0.75974,400

    Contact Details

    377 Plantation Street
    1st floor
    Worcester, MA 01605
    United States

    Webiste:MBIO

    781 652 4500

    Company Information

    Employees-

    Beta1.65

    Sales or Revenue0

    5Y Sales Change-

    Fiscal Year Ends2021-12-30

    SectorHealth Care

    IndustryBiotechnology

    About Company

    Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline focuses on gene therapy programs for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors. The company develops MB-107 and MB-207, a gene therapy program for X-linked severe combined immunodeficiency, a rare genetic immune system condition in which affected patients do not live beyond infancy without treatment. The company also develops MB-102 CAR T therapies for blastic plasmacytoid dendritic cell neoplasm, acute myeloid leukemia, and myelodysplastic syndrome; MB-106 CAR T cell program for B cell non-hodgkin lymphoma and chronic lymphocytic leukemia; MB-104 CAR T for multiple myeloma and light chain amyloidosis; MB-101 CAR T cell program for glioblastoma; MB-103 CAR T for glioblastoma multiforme (GBM) and metastatic breast cancer to brain; MB-105 CAR T for prostate and pancreatic cancers; and MB-108, a next-generation oncolytic herpes simplex virus. It has license agreements with Nationwide Children's Hospital, CSL Behring; Mayo Clin Mayo Clinic; Leiden University Medical Centre; SIRION Biotech GmbH, and Minaris Regenerative Medicine GmbH. The company was incorporated in 2015 and is headquartered in Worcester, Massachusetts.

    Frequently Asked Questions

    icon

    What is the current Mustang Bio, Inc. (MBIO) stock price?

    Mustang Bio, Inc. (NASDAQ: MBIO) stock price is $0.7023 as of the last check on Wednesday, August 17. During the trading session, MBIO stock reached the peak price of $0.75 while $0.67 was the lowest point it dropped to.

    icon

    MBIO's industry and sector of operation?

    The NASDAQ listed MBIO is part of Biotechnology industry that operates in the broader Health Care sector. Mustang Bio, Inc. , a clinical-stage biopharmaceutical company, focuses on translating medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors, and rare genetic diseases.

    icon

    Who are the executives of MBIO?

    Mr. Brian K. Achenbach M.B.A.
    Sr. VP of Fin. & Corp. Controller
    Ms. Debra Manning SPHR
    VP of HR
    Ms. Lynn E. Bayless
    Head of Regulatory Affairs
    Mr. Michael S. Weiss Esq.
    Exec. Chairman

    icon

    What is the MBIO stock price today?

    MBIO stock traded closed the last session at $0.738, which is -$0.03589999999999993 or -4.863180709834724% lower than its previous close of $0.715. MBIO's current trading price is 44.75% lower than its 52-week high of $3.09 where as its distance from 52-week low of 0.51% is -76.11%.

    icon

    How many employees does MBIO have?

    Number of MBIO employees currently stands at -. MBIO operates from 377 Plantation Street, 1st floor, Worcester, MA 01605, United States.

    icon

    Link for MBIO official website?

    Official Webiste of $MBIO is: https://www.mustangbio.com

    icon

    How do I contact MBIO?

    MBIO could be contacted at MBIO operates from 377 Plantation Street, 1st floor, Worcester, MA 01605, United States, or at phone #781 652 4500 and can also be accessed through its website.

    icon

    How many shares of MBIO are traded daily?

    MBIO stock volume for the day was 403,777 shares while in the previous session number of MBIO shares traded was 1,734,427 . The average number of MBIO shares traded daily for last 3 months was 1.03 Million.

    icon

    How much did MBIO change today?

    The percentage change in MBIO stock occurred in the recent session was -4.863180709834724% while the dollar amount for the price change in MBIO stock was -$0.03589999999999993.

    icon

    What price range MBIO stock been trading in?

    In the recent session, the day high for MBIO stock was $0.75 while the low for MBIO stock touched on the day was $0.67.

    icon

    What is the market cap of MBIO currently?

    The market value of MBIO currently stands at 74.91 Million with its latest stock price at $0.7023 and 102.95 Million of its shares outstanding.